Similar antineoplastic effects of nimesulide, a selective COX-2 inhibitor, and prostaglandin E1 on B16-F10 murine melanoma cells

Melanoma Research

Volumn 20, Issue 4, 2010, Pages 273-279

  Tabolacci, Claudio ^a   Lentini, Alessandro ^a   Provenzano, Bruno ^a   Gismondi, Angelo ^a   Rossi, Stefania ^a   Beninati, Simone ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

differentiation; invasion; metalloproteinases; nimesulide; polyamines; prostaglandins; transglutaminase

Indexed keywords

CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; MELANIN; NIMESULIDE; PROSTAGLANDIN E1; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SPERMIDINE; SPERMINE; ANTINEOPLASTIC AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONAMIDE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL INVASION; CELL STRUCTURE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; MELANOGENESIS; MELANOMA B16; MELANOMA CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ZYMOGRAPHY; ANIMAL; BIOSYNTHESIS; CELL GROWTH; DRUG EFFECTS; ENZYMOLOGY; MELANOMA, EXPERIMENTAL; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ALPROSTADIL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANINS; MELANOMA, EXPERIMENTAL; SULFONAMIDES; TRANSGLUTAMINASES;

EID: 77954657691     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328339d8ac     Document Type: Article

References (54)

1. Herschaman HR. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev 1994; 13:241-256.
2. Taub M, Borsick M, Geisel J, Matlhagela K, Rajkhowa T, Allen C. Regulation of the Na,K-ATPase in MDCK cells by prostaglandin E1: a role for calcium as well as cAMP. Exp Cell Res 2004; 299:1-14.
3. Gaskill HV. Intraportal prostaglandin E1 ameliorates the toxicity of intraportal 20-deoxy-5-fluorouridine in rats. J Surg Res 1987; 43:128-132.
4. Ikeguchi M, Maeta M, Kaibara N. Cisplatin combined with prostaglandin E1 chemotherapy in rat peritoneal carcinomatosis. Int J Cancer 2000; 88:474-478.
5. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci 1992; 89:7384-7388.
6. Marshall JC, Fernandes BF, Di Cesare S, Maloney SC, Logan PT, Antecka E, et al. The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. Carcinogenesis 2007; 28:2053-2058.
7. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93:705-716.
8. Gupta S, Srivastava M, Ahmad N, Bostwich DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42:73-78.
9. Crosby CG, DuBois RN. The cyclooxygenase-2 pathway as a target for treatment or prevention cancer. Expert Opin Emerg Drugs 2003; 8:1-7.
10. Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumourigenesis. J Cell Mol Med 2003; 7:207-222.
11. Nystrom ML, McCulloch D, Weinreb PH, Violette SM, Speight PM, Marshall JF, et al. Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion. Cancer Res 2006; 66:10833-10842.
12. Iwata C, Kano MR, Komuro A, Oka M, Kiyono K, Johansson E, et al. Inhibition of cyclooxygenase-2 suppresses lymphonode metastasis via reduction of lymphangiogenesis. Cancer Res 2007; 67:10181-10189.
13. Becker MR, Siegelin MD, Rompel R, Enk AH, Gaiser T. COX-2 expression in malignant melanoma: a novel prognostic marker? Melanoma Res 2009; 19:8-16.
14. Denkert C, Köbel M, Berger S, Siegert A, Leclere A, Trefzer U, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001; 61:303-308.
15. Chwirot BW, Kubicki L. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours. Melanoma Res 2007; 17:139-145.
16. Minter HA, Eveson JW, Huntley S, Elder DJ, Hague A. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res 2003; 9:1885-1897.
17. Famaey JP. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overwiew. Inflamm Res 1997; 46: 437-446.
18. Fukutake M, Nakatsugi S, Isoi T, Takahashi M, Ohta T, Mamiya S, et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2 on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis (Lond) 1998; 19:1939-1942.
19. Hida T, Kozaki KI, Muramatusu H, Masuda A, Shimizu S, Mitsudomi T, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000; 6:2006-2011.
20. Funahashi H, Satake M, Dawson D, Huynh NA, Reber HA, Hines OJ, et al. Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res 2007; 67:7068-7071.
21. Heby O. Role of polyamines in the control of cell proliferation and differentiation. Differentiation 1981; 19:1-20. (Pubitemid 11091193)
22. Folk JE. Transglutaminases. Ann Rev Biochem 1980; 49:517-531.
23. Beninati S, Piacentini M. The transglutaminase family: an overview. Amino Acids 2004; 26:367-372.
24. Lentini A, Abbruzzese A, Caraglia M, Marra M, Beninati S. Protein-polyamine conjugation by transglutaminase in cancer cell differentiation: review article. Amino Acids 2004; 26:331-337.
25. Lentini A, Autuori F, Mattioli P, Abbruzzese A, Beninati S. Evaluation of the efficacy of potential antineoplastic drugs on tumour metastasis by a computer-assisted image analysis. Eur J Cancer 2000; 36:1572-1577.
26. Lentini A, Provenzano B, Tabolacci C, Beninati S. Protein-polyamine conjugates by transglutaminase 2 as potential markers for antineoplastic screening of natural compounds. Amino Acids 2009; 36:701-708.
27. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115:3719-3727.
28. Fidler IJ. Selection of successive tumour cell lines for metastasis. Nature (New Biol) 1973; 245:148-149.
29. Chung SI, Folk JE. Transglutaminase from hair follicle of guinea pig. Proc Natl Acad Sci (Wash) 1972; 69:303-307.
30. Lotan R, Lotan D. Stimulation of melanogenesis in a human melanoma cell by retinoids. Cancer Res 1980; 40:3345-3350.
31. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, et al. A rapid in vitro assay for quantitating the invasive potential of tumour cells. Cancer Res 1987; 47:3239-3245.
32. Troeberg L, Nagase H. Methods in molecular biology. Vol.225. Totowa, NJ: Humana Press Inc; 2003. pp. 77-87.
33. Zurier RB. Role of prostaglandins E in inflammation and immune response. Adv Prostaglandin Tromboxane Leukot Res 1991; 21B:947-953.
34. Zweifel BS, Davis TW, Ornberg RL, Masferrer JL. Direct evidence for a role of cyclooxygenase-2 derived prostaglandin E2 in human head and neck xenograft tumours. Cancer Res 2002; 62:6706-6711.
35. Sarkar FH, Yiwei L. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 2006; 66:3347-3350.
36. Bundscherer A, Hafner C, Maisch T, Becker B, Landthaler M, Vogt T. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol Rep 2008; 19:547-553.
37. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999; 59:4356-4362.
38. Badawi AF. The role of prostaglandin synthesis in prostate cancer. BJU Int 2000; 85:451-462.
39. Borrego JF, Cartagena JC, Engel J. Treatment of feline mammary tumours using chemotherapy, surgery and a COX-2 inhibitor drug (meloxicam): a retrospective study of 23 cases (2002-2007). Vet Comp Oncol 2009; 7:213-221.
40. Lejeune FJ, Monnier Y, Rüegg C. Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. Melanoma Res 2006; 16:263-265.
41. Stoehlmacher J, Lenz HJ. Cyclooxygenase-2 inhibitors in colorectal cancer. Semin Oncol 2003; 30:10-16.
42. Bhatt RS, Merchan J, Parker R,Wu HK, Zhang L, Seery V, et al. A phase 2 pilot trial of low-dose, continuous infusion, or 'metronomic' paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 2010; 116:1751-1756.
43. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K. Cyclooxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancers. J Gastrointest Cancer 2007; 38:78-82.
44. Oba M, Miwa K, Fujimura T, Harada S, Sasaki S, Oyama K, et al. A selective cyclooxygenase-2 inhibitor prevents inflammation-related squamous cell carcinogenesis of the forestomach via duodenogastric reflux in rats. Cancer 2009; 115:454-464.
45. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL,Woerner BM, et al. Antiangiogenic and antitumour activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60:1306-1311.
46. Kim BM, Won J, Maeng KA, Han YS, Yun YS, Hong SH. Nimesulide, a selective COX-2 inhibitor, acts synergistically with ionizing radiation against A549 human lung cancer cells through the activation of caspase-8 and caspase-3. Int J Oncol 2009; 34:1467-1473.
47. Dannenberg AJ, Altorki NK, Boyle JO. Cyclooxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001; 2:544-551.
48. Kawase T, Ogata S, Orikasa M, Burns DM. 1.25-Dihydroxyvitamin D3 promotes prostaglandin E1-induced differentiation of HL-60 cells. Calcif Tissue Int 1995; 57:359-366.
49. Fesus L, Madi A, Balajthy Z. Transglutaminase induction by various cell death and apoptosis pathways. Experientia 1996; 52:942-949.
50. Russell DH. Clinical relevance of polyamines as biochemical markers of tumour kinetics. Clin Chem 1977; 23:22-27.
51. Tabor CW, Tabor H. Polyamines in microorganisms. Microbiol Rev 1985; 49:81-99.
52. Gismondi A, Lentini A, Tabolacci C, Provenzano B, Beninati S. Transglutaminase-dependent antiproliferative and differentiative properties of nimesulide on B16-F10 mouse melanoma cells. Amino Acids 2009; 38:257-262.
53. Thiele CJ, Gore S, Collins S, Waxman S, Miller W. Differentiate or die: the view from Montreal. Cell Death Differ 2000; 7:1014-1017.
54. Lentini A, Forni C, Provenzano B, Beninati S. Enhancement of transglutaminase activity and polyamine depletion in B16-F10 melanoma cells by flavonoids naringenin and hesperitin correlate to reduction of the in vivo metastatic potential. Amino Acids 2007; 32:95-100.